Cost-minimization comparison of infusion based FOLFIRI (5-fluorouracil and leucovorin) versus oral based XELIRI (capecitabine and irinotecan) in metastatic colorectal cancer (mCRC).

被引：0
|
作者：
Baran, R
McKenna, E
Patt, Y
Ghali, N
机构：
[1] Roche Biomed Labs, Nutley, NJ USA
[2] Univ Maryland, Med Ctr, Baltimore, MD 21201 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2004年 / 22卷 / 14期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3762
引用
收藏
页码：309S / 309S
页数：1
相关论文
共 50 条
  • [1] COST-MINIMIZATION ANALYSIS OF CAPECITABINE VERSUS UFT/LEUCOVORIN FOR THE TREATMENT OF METASTATIC COLORECTAL CANCER (MCRC) IN BRAZIL
    Saggia, M. G.
    Nasciben, V. D.
    Santos, E. A.
    Stefani, S.
    VALUE IN HEALTH, 2008, 11 (06) : A474 - A474
  • [2] Bimonthly leucovorin, infusion 5-fluorouracil, hydroxyurea, and irinotecan (FOLFIRI-2) for pretreated metastatic colorectal cancer
    Mabro, M
    Louvet, C
    André, T
    Carola, E
    Gilles-Amar, V
    Artru, P
    Krulik, M
    de Gramont, A
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2003, 26 (03): : 254 - 258
  • [3] Cost minimization comparison of oral UFT/leucovorin versus 5-fluorouracil/leucovorin as adjuvant therapy for colorectal cancer in Taiwan
    Hsu, Tzu-Chi
    Wang, Chi-Chuan
    JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2019, 8 (02) : 73 - 79
  • [4] COST-MINIMIZATION ANALYSIS OF CAPECITABINE VERSUS 5-FLUOROURACIL FOR THE TREATMENT OF METASTATIC COLORECTAL CANCER: A DECISION TREE MODEL APROACH
    Lau, M. S.
    Dusetzina, S. B.
    VALUE IN HEALTH, 2016, 19 (03) : A153 - A153
  • [5] 5-FLUOROURACIL, LEUCOVORIN AND IRINOTECAN (FOLFIRI) PLUS BEVACIZUMAB (BV) IN PATIENTS WITH METASTATIC COLORECTAL CANCER (MCRC): A MULTICENTER PHASE II TRIAL
    Cordio, S.
    Parra, Soto H. J.
    Pumo, V
    Condorelli, S.
    Latteri, F.
    Sambataro, D.
    Rosati, G.
    Aprile, G.
    Fassari, G.
    De Pauli, F.
    Rimassa, L.
    Bordonaro, R.
    ANNALS OF ONCOLOGY, 2009, 20
  • [6] COST-MINIMIZATION ANALYSIS OF CAPECITABINE VERSUS UFT/LEUCOVORIN FOR THE TREATMENT OF METASTATIC COLORECTAL CANCER (MCRC), ACCORDING TO THE RECOMMENDED BRAZILIAN GUIDELINES FOR HTA
    Saggia, M. G.
    Nasciben, V. D.
    Santos, E. V.
    ANNALS OF ONCOLOGY, 2008, 19 : 148 - 148
  • [7] Panitumumab therapy with irinotecan, 5-fluorouracil, and leucovorin (IFL) in patients (pts) with metastatic colorectal cancer (mCRC)
    Berlin, Jordan
    Malik, Imtiaz
    Picus, Joel
    Glisson, Shawn
    Kozloff, Mark
    Spitzer, Gary
    Wiens, Brian
    MacDonald, Monica
    Jerian, Susan
    Hecht, J. Randolph
    ANNALS OF ONCOLOGY, 2004, 15 : 70 - 71
  • [8] THE BUDGETARY IMPACT OF GENETIC-GUIDED DOSING OF 5-FLUOROURACIL, IRINOTECAN, LEUCOVORIN, AND BEVACIZUMAB (FOLFIRI plus BEV) IN METASTATIC COLORECTAL CANCER (MCRC)
    Rivers, Z.
    Stenehjem, D.
    Jacobson, P.
    Lou, E.
    Nelson, A.
    Kuntz, K. M.
    VALUE IN HEALTH, 2020, 23 : S42 - S42
  • [9] Meta-analysis comparing the safety and efficacy of metastatic colorectal cancer treatment regimens, capecitabine plus irinotecan (CAPIRI) and 5-fluorouracil/leucovorin plus irinotecan (FOLFIRI)
    Ding, Hong-hua
    Wu, Wei-dong
    Jiang, Tao
    Cao, Jun
    Ji, Zheng-yi
    Jin, Jia-huan
    Wang, Jing-jue
    Song, Wei-feng
    Wang, Li-wei
    TUMOR BIOLOGY, 2015, 36 (05) : 3361 - 3369
  • [10] Impact of Early Tumour Shrinkage on Long-term Outcome In Metastatic Colorectal Cancer (mCRC) Treated With 5FU+Irinotecan plus Leucovorin (FOLFIRI) or Capecitabine plus Irinotecan XELIRI Plus Bevacizumab
    Ichante, J. L.
    Adenis, A.
    Francois, E.
    Boucher, E.
    Pignon, J. P.
    Ychou, M.
    Pierga, J. Y.
    Montotot-Grillo, C.
    Conroy, T.
    Ducreux, M.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S419 - S419
12345